These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29800105)

  • 1. Simultaneous Determination of Elbasvir and Grazoprevir in Their Pharmaceutical Preparation Using High-Performance Liquid Chromatographic Method.
    Attia KAM; El-Abasawi NM; El-Olemy A; Abdelazim AH; El-Dosoky M
    J Chromatogr Sci; 2018 Sep; 56(8):731-737. PubMed ID: 29800105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous Spectrophotometric Determination of Elbasvir and Grazoprevir in a Pharmaceutical Preparation.
    Attia KAM; El-Abasawi NM; El-Olemy A; Abdelazim AH
    J AOAC Int; 2018 Mar; 101(2):394-400. PubMed ID: 28766477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of different spectrophotometric methods for simultaneous determination of elbasvir and grazoprevir in pharmaceutical preparation.
    Attia KAM; El-Abasawi NM; El-Olemy A; Abdelazim AH
    Spectrochim Acta A Mol Biomol Spectrosc; 2018 Jan; 189():154-160. PubMed ID: 28806701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous determination of elbasvir and grazoprevir in their pharmaceutical formulation by synchronous fluorescence spectroscopy coupled to dual wavelength method.
    Attia KAM; El-Olemy A; Ramzy S; Abdelazim AH; Hasan MA; Abdel-Kareem RF
    Spectrochim Acta A Mol Biomol Spectrosc; 2021 Mar; 248():119157. PubMed ID: 33218874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous spectrophotometric quantitative analysis of elbasvir and grazoprevir using assisted chemometric models.
    Zeid AM; Abdelazim AH; Shahin M
    Spectrochim Acta A Mol Biomol Spectrosc; 2021 May; 252():119505. PubMed ID: 33561683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous determination of elbasvir and grazoprevir in fixed-dose combination and mass spectral characterization of each degradation product by UHPLC-ESI-QTOF-MS/MS.
    Chen L; Chen J; Lu M; Stämpfli A
    J Pharm Biomed Anal; 2020 Jan; 178():112964. PubMed ID: 31711865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
    Sulkowski M; Hezode C; Gerstoft J; Vierling JM; Mallolas J; Pol S; Kugelmas M; Murillo A; Weis N; Nahass R; Shibolet O; Serfaty L; Bourliere M; DeJesus E; Zuckerman E; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
    Lancet; 2015 Mar; 385(9973):1087-97. PubMed ID: 25467560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic similarity demonstrated after crushing of the elbasvir/grazoprevir fixed-dose combination tablet for HCV infection.
    Pijnenburg DWM; van Seyen M; Abbink EJ; Colbers A; Drenth JPH; Burger DM
    J Antimicrob Chemother; 2020 Sep; 75(9):2661-2665. PubMed ID: 32544221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
    Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
    Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.
    Asante-Appiah E; Curry S; McMonagle P; Ingravallo P; Chase R; Nickle D; Qiu P; Howe A; Lahser FC
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
    Kwo P; Gane EJ; Peng CY; Pearlman B; Vierling JM; Serfaty L; Buti M; Shafran S; Stryszak P; Lin L; Gress J; Black S; Dutko FJ; Robertson M; Wahl J; Lupinacci L; Barr E; Haber B
    Gastroenterology; 2017 Jan; 152(1):164-175.e4. PubMed ID: 27720838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elbasvir/Grazoprevir: First Global Approval.
    Keating GM
    Drugs; 2016 Apr; 76(5):617-24. PubMed ID: 26943930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Grazoprevir + elbasvir for the treatment of hepatitis C virus infection.
    Alric L; Bonnet D
    Expert Opin Pharmacother; 2016; 17(5):735-42. PubMed ID: 26933896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3.
    Yeh WW; Fraser IP; Jumes P; Petry A; Lepeleire I; Robberechts M; Reitmann C; Van Dyck K; Huang X; Guo Z; Panebianco D; Nachbar RB; O'Mara E; Wagner JA; Butterton JR; Dutko FJ; Moiseev V; Kobalava Z; Hüser A; Visan S; Schwabe C; Gane E; Popa S; Ghicavii N; Uhle M; Wagner F
    Clin Ther; 2018 May; 40(5):704-718.e6. PubMed ID: 29703432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HPLC-UV and TLC-Densitometry Methods for Simultaneous Determination of Sofosbuvir and Daclatasvir: Application to Darvoni® Tablet.
    Fayed AS; Hegazy MA; Kamel EB; Eissa MS
    J Chromatogr Sci; 2022 Jul; 60(6):606-612. PubMed ID: 34355234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.
    Lawitz E; Gane E; Pearlman B; Tam E; Ghesquiere W; Guyader D; Alric L; Bronowicki JP; Lester L; Sievert W; Ghalib R; Balart L; Sund F; Lagging M; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
    Lancet; 2015 Mar; 385(9973):1075-86. PubMed ID: 25467591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elbasvir/grazoprevir (Zepatier) for hepatitis C.
    Med Lett Drugs Ther; 2016 Feb; 58(1489):25-7. PubMed ID: 26938699
    [No Abstract]   [Full Text] [Related]  

  • 18. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.
    Bruchfeld A; Roth D; Martin P; Nelson DR; Pol S; Londoño MC; Monsour H; Silva M; Hwang P; Arduino JM; Robertson M; Nguyen BY; Wahl J; Barr E; Greaves W
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):585-594. PubMed ID: 28576451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RP-HPLC method development and validation for quantification of daclatasvir dihydrochloride and its application to pharmaceutical dosage form.
    Hussain Shah SS; Nasiri MI; Sarwar H; Ali A; S Naqvi SB; Anwer S; Kashif M
    Pak J Pharm Sci; 2021 May; 34(3):951-956. PubMed ID: 34602418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.
    Lahser FC; Bystol K; Curry S; McMonagle P; Xia E; Ingravallo P; Chase R; Liu R; Black T; Hazuda D; Howe AY; Asante-Appiah E
    Antimicrob Agents Chemother; 2016 May; 60(5):2954-64. PubMed ID: 26926625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.